Cart
sales@molnova.com
Anlotinib Dihydrochloride
CAS No. 1360460-82-7
Anlotinib Dihydrochloride( Anlotinib (AL3818) dihydrochloride | AL3818 dihydrochloride )
Catalog No. M19393 CAS No. 1360460-82-7
Anlotinib also known as AL3818 is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAnlotinib Dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionAnlotinib also known as AL3818 is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities.
-
DescriptionAnlotinib also known as AL3818 is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration anlotininib targets multiple RTKs including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.
-
In Vitro——
-
In Vivo——
-
SynonymsAnlotinib (AL3818) dihydrochloride | AL3818 dihydrochloride
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR2| VEGFR3|c-Kit
-
Research AreaCancer
-
IndicationNon-small cell lung Cancer
Chemical Information
-
CAS Number1360460-82-7
-
Formula Weight480.36
-
Molecular FormulaC23H24Cl2FN3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:87 mg/mL(181.1 mM)
-
SMILESCc1cc2c([nH]1)ccc(c2F)Oc1c2cc(c(cc2ncc1)OCC1(CC1)N)OC.Cl.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Tyrosine kinase-IN-1
Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor(KDR Flt-1 FGFR1 and PDGFRα with IC50s of 4nM 20nM 4nM 2 nM respectively).
-
Apatinib Mesylate
Apatinib (YN968D1) is a multitargeted tyrosine kinase inhibitor (TKI) that inhibits VEGFR-2 (Flk-1/KDR, IC50=1 nM), RET, c-Kit and c-Src (IC50=13, 429 and 530 nM respectively).
-
Lariciresinol
Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for the treatment of fungal infectious diseases in humans. Dietary lariciresinol can attenuate mammary tumor growth and reduce blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.
